Artivion (NYSE:AORT) SVP Sells 1,493 Shares of Stock

by · The Markets Daily

Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Andrew Green sold 1,493 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total value of $38,847.86. Following the sale, the senior vice president owned 51,640 shares in the company, valued at approximately $1,343,672.80. This trade represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Down 0.0%

Shares of AORT traded down $0.01 during midday trading on Friday, hitting $25.61. The company had a trading volume of 139,212 shares, compared to its average volume of 597,321. The company’s 50-day simple moving average is $26.05 and its 200-day simple moving average is $29.23. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The firm has a market capitalization of $1.25 billion, a P/E ratio of -365.49 and a beta of 1.25. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25.

Artivion (NYSE:AORT – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, sell-side analysts expect that Artivion, Inc. will post 0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AORT. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the 3rd quarter worth $27,000. Rockefeller Capital Management L.P. boosted its stake in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Artivion during the fourth quarter worth about $79,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Canaccord Genuity Group increased their target price on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Get Our Latest Stock Analysis on AORT

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

Read More